The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: Comparison with RECIST and tumour density criteria

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 9, 2012, Pages 1391-1399

  Zerizer, I ^a   Al Nahhas, A ^a   Towey, D ^a   Tait, P ^a   Ariff, B ^a   Wasan, H ^a   Hatice, G ^a   Habib, N ^a   Barwick, T ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

90Y Radioembolization; PET CT; Response assessment

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TUMOR MARKER; YTTRIUM 90; CONTRAST MEDIUM; DIAGNOSTIC AGENT; YTTRIUM;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER PROGNOSIS; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; LIVER METASTASIS; MALE; PROGRESSION FREE SURVIVAL; RADIATION RESPONSE; RADIOLOGICAL PARAMETERS; STATISTICAL ANALYSIS; SURVIVAL PREDICTION; TREATMENT RESPONSE; BLOOD; COLORECTAL TUMOR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING; TIME; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; COLORECTAL NEOPLASMS; CONTRAST MEDIA; DISEASE-FREE SURVIVAL; EMBOLIZATION, THERAPEUTIC; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; YTTRIUM RADIOISOTOPES;

EID: 84865634822     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2149-1     Document Type: Article

References (20)

1. B Nordlinger M Guiguet JC Vaillant P Balladur K Boudjema P Bachellier, et al. 1996 Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie Cancer 77 1254 1262 8608500 10.1002/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.0.CO;2-I 1:STN:280:DyaK287pslCiuw%3D%3D
2. I Taylor R Bennett S Sherriff 1978 The blood supply of colorectal liver metastases Br J Cancer 38 749 756 743492 10.1038/bjc.1978.283 1:STN:280:DyaE1M7isVGltg%3D%3D
3. A Deleporte P Flamen A Hendlisz 2010 State of the art: radiolabeled microspheres treatment for liver malignancies Expert Opin Pharmacother 11 579 586 20163269 10.1517/14656560903520916
4. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280: DC%2BD3c7it1Gitg%3D%3D
5. J Bruix M Sherman JM Llovet M Beaugrand R Lencioni AK Burroughs, et al. 2001 Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 421 430 11592607 10.1016/S0168-8278(01)00130-1 1:STN:280: DC%2BD3MrksFCmtg%3D%3D
6. H Choi C Charnsangavej SC Faria HA Macapinlac MA Burgess SR Patel, et al. 2007 Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 1753 1759 17470865 10.1200/JCO.2006.07.3049
7. WA Weber 2006 Positron emission tomography as an imaging biomarker J Clin Oncol 24 3282 3292 16829652 10.1200/JCO.2006.06.6068 1:CAS:528: DC%2BD28Xot1yhsr8%3D
8. SM Larson LH Schwartz 2006 18F-FDG PET as a candidate for 'qualified biomarker': functional assessment of treatment response in oncology J Nucl Med 47 901 903 16741296 1:CAS:528:DC%2BD28XmtlWmsbk%3D
9. WA Weber 2005 Use of PET for monitoring cancer therapy and for predicting outcome J Nucl Med 46 983 995 15937310 1:CAS:528:DC%2BD28XitFSqtrg%3D
10. R Dierckx A Maes M Peeters C Van De Wiele 2009 FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases Q J Nucl Med Mol Imaging 53 336 342 19521313 1:STN:280:DC%2BD1MvhsVCgug%3D%3D
11. AD Van den Abbeele 2008 The lessons of GIST-PET and PET/CT: a new paradigm for imaging Oncologist 13 Suppl 2 8 13 18434632 10.1634/theoncologist. 13-S2-8
12. H Young R Baum U Cremerius K Herholz O Hoekstra AA Lammertsma, et al. 1999 Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 1773 1782 10673991 10.1016/S0959- 8049(99)00229-4 1:STN:280:DC%2BD3c7jvV2ntA%3D%3D
13. MP Mac Manus RJ Hicks JP Matthews A McKenzie D Rischin EK Salminen, et al. 2003 Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer J Clin Oncol 21 1285 1292 12663716 10.1200/JCO.2003.07.054
14. RL Wahl H Jacene Y Kasamon MA Lodge 2009 From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 Suppl 1 122S 150S 19403881 10.2967/jnumed.108.057307 1:CAS:528:DC%2BD1MXmtFahtr8%3D
15. EA Eisenhauer P Therasse J Bogaerts LH Schwartz D Sargent R Ford, et al. 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228 247 19097774 10.1016/j.ejca.2008.10.026 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D
16. CY Wong R Salem S Raman VL Gates HJ Dworkin 2002 Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI Eur J Nucl Med Mol Imaging 29 815 820 12029557 10.1007/s00259-002-0787-4 1:CAS:528:DC%2BD38XlvVWms7s%3D
17. G Popperl T Helmberger W Munzing R Schmid TF Jacobs K Tatsch 2005 Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors Cancer Biother Radiopharm 20 200 208 15869456 10.1089/cbr.2005.20.200
18. T Szyszko A Al Nahhas R Canelo N Habib L Jiao H Wasan, et al. 2007 Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography Nucl Med Commun 28 15 20 17159544 10.1097/MNM.0b013e328011453b
19. CY Wong R Salem F Qing KT Wong D Barker V Gates, et al. 2004 Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET J Nucl Med 45 1892 1897 15534060 1:CAS:528:DC%2BD2cXhtVKnur3E
20. V Goh AR Padhani 2006 Imaging tumor angiogenesis: functional assessment using MDCT or MRI? Abdom Imaging 31 194 199 16333695 10.1007/s00261-005-0387-4 1:STN:280:DC%2BD287nslGjug%3D%3D